vs 7,393 other HR bills in the 115th — cohort avg 50d
Summary
Working to Integrate Networks Guaranteeing Member Access Now Act or the WINGMAN Act (Sec. 2) This bill directs the Department of Veterans Affairs (VA) to provide each veteran who submits a claim for VA benefits with an opportunity to permit a covered congressional employee in the office of the veteran's Member of Congress to have read-only access to all of the veteran's records in the Veterans Benefits Administration databases. A Member may designate up to two such covered congressional employees. A covered congressional employee may not be recognized as an agent or attorney with respect to veterans' benefit claims. Funds under this bill may not be used to design or administer any training for covered congressional employees. The bill makes up to $10 million available for obligation or expenditure for FY2018 through FY2021 for such congressional employee access program. No additional funds are authorized to be appropriated to carry out the bill.
Lobbying filings that explicitly cite this bill (16)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Maritime Administration (MARAD), Natl Archives & Records Administration (NARA), Navy, Dept of, SENATE, U.S. Coast Guard (USCG), Veterans Affairs, Dept of (VA), White House Office
Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Maritime Administration (MARAD), Natl Archives & Records Administration (NARA), Navy, Dept of, SENATE, U.S. Coast Guard (USCG), Veterans Affairs, Dept of (VA), White House Office
Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Maritime Administration (MARAD), Natl Archives & Records Administration (NARA), Navy, Dept of, SENATE, U.S. Coast Guard (USCG), Veterans Affairs, Dept of (VA), White House Office
Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Maritime Administration (MARAD), Natl Archives & Records Administration (NARA), Navy, Dept of, SENATE, U.S. Coast Guard (USCG), Veterans Affairs, Dept of (VA), White House Office
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $80,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $90,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $80,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $80,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $160,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $140,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $110,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R. 27 Ensuring VA Employee Accountability;H.R. 28 Biological Implant Tracking and Veteran Safety;H.R. 42 To authorize VISN of the VA to enter into contrs with appropriate civilian accreditation entities or appropriate health care evaluation entities to investigate medical centers of the VA;H.R. 90 Providing Veterans Overdue Care;H.R. 91 Building Supportive Networks for Women Veterans;H.R. 92 CHAMPVA Children's Protection;H.R. 93 To increase access to VA care for women vets;H.R. 95 Veterans' Access to Child Care;H.R. 101 Veterans Healthcare Improvement;H.R. 102 Expanding Care for Veterans;H.R. 103 Chiropric Care Available to All Veterans;H.R. 105 Protect Veterans from Financial Fraud ;H.R. 299 Blue Water Navy Vietnam Veterans;H.R. 369 To eliminate the sunset of the Veterans Choice Program;H.R. 388 Veterans Health Equity ;H.R. 411 Veteran Suicide Prevention;H.R. 418 Early Intervention for Veterans and their Families;H.R. 467 VA Scheduling Accountability;H.R. 476 VET;H.R. 501 VA Transparency Enhancement;H.R. 512 WINGMAN;H.R. 544 Purple Heart Preservation;H.R. 632 Atomic Veterans Healthcare Parity;H.R. 907 Newborn Care Improvement;H.R. 918 Veteran Urgent Access to Mental Healthcare;H.R. 1005 Improve adult day health care services for veterans;H.R. 1112 Shauna Hill Post 9/11 Education Benefits Transferability;H.R. 1162 No Hero Left Untreated;H.R. 1259 VA Accountability First;H.R. 1328 Vets COLA;H.R. 1329 Vets COLA;H.R. 1472 Military and Veteran Caregiver Services Improvement;H.R. 1545 VA Prescription Data Accountability;H.R. 1564 VA Beneficiary Travel;S. 66 Retired Pay Restoration;S. 86 Veterans Choice Continuation;S. 115 Veterans Transplant Coverage;S. 422 Blue Water Navy Vietnam Veterans;S. 423 CHAMPVA Children's Care Protection;S. 591 Military and Veteran Caregiver Services Improvement;S. 764 Veterans Education Priority Enrollment;
Cited source text, amounts, lobbyists, and targets
Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)
Client expense: $110,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Maritime Administration (MARAD), Natl Archives & Records Administration (NARA), Navy, Dept of, SENATE, U.S. Coast Guard (USCG), Veterans Affairs, Dept of (VA), White House Office
Client expense: Not reported · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Maritime Administration (MARAD), Natl Archives & Records Administration (NARA), Navy, Dept of, SENATE, U.S. Coast Guard (USCG), Veterans Affairs, Dept of (VA), White House Office
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
Client expense: $423,683 · Firm income: Not reported
Government targets: Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Consumer Financial Protection Bureau (CFPB), Defense Commissary Agency, Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Government Accountability Office (GAO), Government Printing Office (GPO), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Natl Guard, Natl Oceanic & Atmospheric Administration (NOAA), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), Office of the Secretary of Defense, President of the U.S., SENATE, U.S. Coast Guard (USCG), U.S. Marines, Veterans Affairs, Dept of (VA), Veterans Employment & Training Service
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE